Biotechnology

Madrigal Pharma

Madrigal Pharmaceuticals Reports Q1 2026 Net Loss Widens to $94.39M Despite Strong Rezdiffra Revenue Amidst Uncertainty

Madrigal's Rezdiffra Strong Sales, ZSP1601 Shows Potential in Anti-Fibrotic Therapy

Madrigal Pharma released FY2026 Q1 earnings on May 6 Pre-Market (EST), actual revenue USD 311.34 M (forecast USD 300.92 M), actual EPS USD -3.2512 (forecast USD -4.0425)

Arrowhead Pharmaceuticals Licenses MASH Therapy to Madrigal Pharmaceuticals

Madrigal Pharma to Release FY2026 Q1 Earnings on May 6 Pre-Market EST, Forecast Revenue USD 301.65 M, EPS USD -4.0425

Madrigal Pharma released FY2025 annual earnings on February 19 Pre-Market EST, actual revenue USD 958.4 M (forecast USD 949.73 M), actual EPS USD -12.8501 (forecast USD -10.7609)

Madrigal Pharma released FY2025 Q4 earnings on February 19 Pre-Market (EST), actual revenue USD 0 (forecast USD 312.74 M), actual EPS USD 0 (forecast USD -0.5384)

Skandinaviska Enskilda Banken AB Significantly Increases Holdings in Madrigal Pharmaceuticals

Madrigal Pharma to release FY2025 Q4 earnings on February 19, Pre-Market EST; forecast revenue USD 312.72 M, EPS USD -0.4654

Madrigal Enters into Global License Agreement with Suzhou Ribobi Life Science to Expand MASH Treatment Pipeline

Madrigal Pharmaceuticals Showcases Pfizer Assets and Rezdiffra Success, Aims to Lead MASH Market

Madrigal Pharmaceuticals Director Rebecca Taub Sells Company Common Stock

TD Cowen analyst upgrades Madrigal Pharmaceuticals target price to 644 USD

Madrigal Pharmaceuticals secures global exclusive license for ervogastat

Piper Sandler Raises Madrigal Pharmaceuticals' Target Price to $900

B. Riley Securities Raises Madrigal Pharmaceuticals Target Price to $670

Madrigal Pharmaceuticals insiders sold $1,380,816 worth of shares

Madrigal Pharmaceuticals CEO Plans to Sell 2,400 Shares of Restricted Stock

Galmed Pharmaceuticals Grants New Use Patent for ARAMCHOL in Combination with Madrigal Pharmaceuticals' REZDIFFRA

Madrigal Pharmaceuticals CFO Reports on Stock Disposal

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

MDGL

LABU

SBIO

ARKG

Madrigal Pharmaceuticals reported a Q1 2026 net loss of $94.39 million, up from $73.24 million a year prior, despite strong revenue growth from Rezdiffra. The company emphasizes the importance of Rezdiffra's commercial uptake and physician adoption for its investment narrative. Rising costs and reimbursement pressures pose risks, while forecasts suggest potential revenue of $2.5 billion by 2028. Analysts' opinions vary significantly, highlighting the uncertainty surrounding Madrigal's financial outlook.

Simplywall

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

VG Health

Invesco Biotechnology & Genome ETF

iShares US Pharma

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders

On May 1, 2026, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) based in Conshohocken, Pennsylvania, disclosed that it provided equity awards to 47 recently hired non-executive staff as inducement awards under the 2025 Inducement Plan. These awards were sanctioned by Madrigal's autonomous Compensation Committee following Nasdaq Listing Rule 5635(c)(4) guidelines. Madrigal focuses on creating innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH).

Unusual Whales

Nasdaq

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Barclays analyst Eliana Merle has maintained a Buy rating on Madrigal Pharmaceuticals (MDGL) with a price target of $964.00. Merle, a 3-star analyst, has an average return of 3.8% and a 41.22% success rate. Additionally, H.C. Wainwright's Andrew Fein also issued a Buy rating for the company, while Bank of America Securities reiterated a Hold rating on the same day.

Tip Ranks

Health Care Select Sector SPDR

Barclays

Alnylam Pharma

Bridgebio Pharma

BioMarin Pharma

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays

Bank of America Securities analyst Jason Zemansky has maintained a Hold rating on Madrigal Pharmaceuticals (MDGL) with a price target of $550. The analyst, known for a 21.3% average return and a 57.59% success rate, covers the Healthcare sector. The consensus on Madrigal Pharmaceuticals is a Strong Buy, with an average price target of $663.89.

iShares Global Healthcare

Ligand Pharmac-B

Insmed

Cytokinetics

Bank of America Securities Sticks to Their Hold Rating for Madrigal Pharmaceuticals (MDGL)

ZNTL

BAYRY

Bayer has agreed to acquire Perfuse Therapeutics for up to $2.45 billion, with $300 million upfront. Madrigal Pharmaceuticals secured a global license for ARO-PNPLA3, a siRNA therapy, for $25 million upfront and up to $975 million in milestones. Zentalis Pharmaceuticals has dosed the first patient in a Phase III trial for a WEE1 inhibitor in ovarian cancer. Brooke Ervin discusses the challenges of translating real-world evidence into actionable clinical decisions in urology, emphasizing the need for better integration of data into clinical workflows.

Pharmexec

ZeZentalis Pharma

Bayer

Bayer AG

ArrowHead Pharma

Bayer Aktiengesellschaft

<![CDATA[Pharmaceutical Executive Daily: Zentalis Doses First Patient with Azenosertib in Phase III Trial]]>

Madrigal Pharmaceuticals reported impressive Q1 2026 results, with net sales of $311 million, a 127% increase year-over-year, driven by their lead product, Rezdifra, which achieved over $1.1 billion in sales in the past year. The company is focused on expanding its market presence and pipeline, including a new SIRNA targeting PNPLA3 mutation. With over 42,250 active patients on Rezdifra, Madrigal aims to leverage its market position for sustained growth in a rapidly expanding market.

benzinga_article

Proshares Ultra Nasdaq Biotech

Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call

CVS Health shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 guidance.

CVS Health

Madrigal Pharma(MDGL.US)